Literature DB >> 18660382

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes".

Anne S De Groot1, Leonard Moise, Julie A McMurry, Erik Wambre, Laurence Van Overtvelt, Philippe Moingeon, David W Scott, William Martin.   

Abstract

We have identified at least 2 highly promiscuous major histocompatibility complex class II T-cell epitopes in the Fc fragment of IgG that are capable of specifically activating CD4(+)CD25(Hi)FoxP3(+) natural regulatory T cells (nT(Regs)). Coincubation of these regulatory T-cell epitopes or "Tregitopes" and antigens with peripheral blood mononuclear cells led to a suppression of effector cytokine secretion, reduced proliferation of effector T cells, and caused an increase in cell surface markers associated with T(Regs) such as FoxP3. In vivo administration of the murine homologue of the Fc region Tregitope resulted in suppression of immune response to a known immunogen. These data suggest that one mechanism for the immunosuppressive activity of IgG, such as with IVIG, may be related to the activity of regulatory T cells. In this model, regulatory T-cell epitopes in IgG activate a subset of nT(Regs) that tips the resulting immune response toward tolerance rather than immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18660382      PMCID: PMC2569179          DOI: 10.1182/blood-2008-02-138073

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  Natural versus adaptive regulatory T cells.

Authors:  Jeffrey A Bluestone; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

2.  Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.

Authors:  Anne S De Groot; Elizabeth A Bishop; Basim Khan; Michelle Lally; Luisa Marcon; Judith Franco; Kenneth H Mayer; Charles C J Carpenter; William Martin
Journal:  Methods       Date:  2004-12       Impact factor: 3.608

3.  Peptide induces CD4(+)CD25+ and IL-10+ T cells and protection in airway allergy models.

Authors:  Cindy L Zuleger; Xiaoyan Gao; Melissa S Burger; Qili Chu; Lendon G Payne; Dexiang Chen
Journal:  Vaccine       Date:  2005-05-02       Impact factor: 3.641

Review 4.  Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins.

Authors:  Hervé Watier
Journal:  Expert Opin Biol Ther       Date:  2005-09       Impact factor: 4.388

5.  Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.

Authors:  Tie Chi Lei; David W Scott
Journal:  Blood       Date:  2005-03-15       Impact factor: 22.113

6.  Molecular analysis of expression and function of hFcgammaRIIbl and b2 isoforms in myeloid cells.

Authors:  Trupti Joshi; Latha P Ganesan; Xianhua Cao; Susheela Tridandapani
Journal:  Mol Immunol       Date:  2005-07-26       Impact factor: 4.407

Review 7.  Recombinant immunoglobulin-based epitope delivery: a novel class of autoimmune regulators.

Authors:  William J Phillips; Dan J Smith; Constantin A Bona; Adrian Bot; Habib Zaghouani
Journal:  Int Rev Immunol       Date:  2005 Sep-Dec       Impact factor: 5.311

8.  DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype.

Authors:  Ivana Durinovic-Belló; Silke Rosinger; Jennifer A Olson; Mauro Congia; Regina C Ahmad; Mathias Rickert; Johannes Hampl; Hubert Kalbacher; Jan W Drijfhout; Elizabeth D Mellins; Sascha Al Dahouk; Thomas Kamradt; Markus J Maeurer; Carol Nhan; Bart O Roep; Bernhard O Boehm; Constantin Polychronakos; Gerald T Nepom; Wolfram Karges; Hugh O McDevitt; Grete Sønderstrup
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-25       Impact factor: 11.205

Review 9.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

Authors:  Jordan S Orange; Elham M Hossny; Catherine R Weiler; Mark Ballow; Melvin Berger; Francisco A Bonilla; Rebecca Buckley; Javier Chinen; Yehia El-Gamal; Bruce D Mazer; Robert P Nelson; Dhavalkumar D Patel; Elizabeth Secord; Ricardo U Sorensen; Richard L Wasserman; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2006-04       Impact factor: 10.793

Review 10.  Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients.

Authors:  S C Jordan; A A Vo; A Peng; M Toyoda; D Tyan
Journal:  Am J Transplant       Date:  2006-03       Impact factor: 8.086

View more
  145 in total

1.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Authors:  Stephen J Schuster; Sattva S Neelapu; Barry L Gause; John E Janik; Franco M Muggia; Jon P Gockerman; Jane N Winter; Christopher R Flowers; Daniel A Nikcevich; Eduardo M Sotomayor; Dean S McGaughey; Elaine S Jaffe; Elise A Chong; Craig W Reynolds; Donald A Berry; Carlos F Santos; Mihaela A Popa; Amy M McCord; Larry W Kwak
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.

Authors:  Qing-Hui Zhou; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; Ruben J Boado; William M Pardridge
Journal:  Brain Res       Date:  2011-01-26       Impact factor: 3.252

4.  Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease.

Authors:  Jagadeesh Bayry; Luc Mouthon; Srini V Kaveri
Journal:  J Rheumatol       Date:  2012-02       Impact factor: 4.666

Review 5.  Immunomodulation by intravenous immunoglobulin: role of regulatory T cells.

Authors:  Mohan S Maddur; Shivashankar Othy; Pushpa Hegde; Janakiraman Vani; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

6.  Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.

Authors:  Qing-Hui Zhou; Rachita Sumbria; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; Ruben J Boado; William M Pardridge
Journal:  J Pharmacol Exp Ther       Date:  2011-08-10       Impact factor: 4.030

Review 7.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

8.  Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Authors:  Judith T Murphy; Andre P Burey; Amy M Beebe; Danling Gu; Leonard G Presta; Taha Merghoub; Jedd D Wolchok
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

Review 9.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

10.  Exploring the immunome: A brave new world for human vaccine development.

Authors:  Anne S De Groot
Journal:  Hum Vaccin       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.